Valuation: BICYCL

Market Cap 249M 222M 207M 189M 354M 24B 360M 2.5B 969M 12.23B 935M 915M 39.39B P/E 2026 *
-1.37x
P/E 2027 * -1.52x
Enterprise Value -264M -234M -219M -200M -375M -25.39B -381M -2.65B -1.03B -12.94B -990M -968M -41.68B EV / Sales 2026 *
-15x
EV / Sales 2027 * -23.1x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2015
Director of Finance/CFO 46 28/01/2026
Chief Tech/Sci/R&D Officer - 31/05/2025
Director TitleAgeSince
Director/Board Member 57 31/08/2015
Director/Board Member 63 16/03/2021
Director/Board Member 69 19/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 258M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -0.04%+1.97%+55.43%+154.28% 44.09B
Weighted average by Cap. +0.17%+1.83%+60.06%+145.78%

Financials

2026 *2027 *
Net sales 17.53M 15.59M 14.57M 13.29M 24.94M 1.69B 25.31M 176M 68.18M 861M 65.82M 64.4M 2.77B 6.69M 5.95M 5.56M 5.07M 9.51M 644M 9.66M 67.11M 26.01M 328M 25.11M 24.57M 1.06B
Net income -172M -153M -143M -130M -245M -16.57B -248M -1.73B -669M -8.45B -646M -632M -27.2B -175M -156M -146M -133M -249M -16.86B -253M -1.76B -681M -8.6B -657M -643M -27.68B
Net Debt -513M -456M -426M -389M -729M -49.39B -740M -5.15B -1.99B -25.17B -1.93B -1.88B -81.07B -403M -359M -335M -306M -574M -38.85B -582M -4.05B -1.57B -19.8B -1.51B -1.48B -63.76B
Logo BICYCL
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-